Dagmar Rosa-Bjorkeson, a director of Intercept Pharmaceuticals, recently acquired 10,543 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on May 27, 2021. Rosa-Bjorkeson now owns 10,543 shares of the company. Rosa-Bjorkeson operates out of New York, NY. Some additional info was provided as follows:
Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 1/3rd of the shares subject to the award shall vest on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year). The Vesting Commencement Date is April 1, 2021.
1/3rd of the options subject to the award shall vest and become exercisable on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year). The Vesting Commencement Date is April 1, 2021.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!
Other recent filings from the company include the following:
Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results And Provides Business Update - Aug. 3, 2022
Intercept Pharmaceuticals Just Filed Its Quarterly Report: 14. Net Loss Per ... - Aug. 3, 2022
Intercept Pharmaceuticals's General Counsel just disposed of 771 shares - Aug. 3, 2022
On July - July 26, 2022
Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 436 shares - July 13, 2022